Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action
# Background Worldwide more than 125 million people are infected with hepatitis C (HCV). New drugs, direct acting antivirals (DAAs) that can cure HCV in three months, are available in generic form at very low cost in over 100 low- and middle-income countries, yet few countries have launched nationa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Inishmore Laser Scientific Publishing Ltd
2019-03-01
|
| Series: | Journal of Global Health Reports |
| Online Access: | https://doi.org/10.29392/joghr.3.e2019011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850100849428135936 |
|---|---|
| author | Robert Hecht Miloud Kaddar Stephen Resch Jean Luc El Kaim Chase Perfect Mustapha Sodqi Hakima Himmich Lindsey Hiebert |
| author_facet | Robert Hecht Miloud Kaddar Stephen Resch Jean Luc El Kaim Chase Perfect Mustapha Sodqi Hakima Himmich Lindsey Hiebert |
| author_sort | Robert Hecht |
| collection | DOAJ |
| description | # Background
Worldwide more than 125 million people are infected with hepatitis C (HCV). New drugs, direct acting antivirals (DAAs) that can cure HCV in three months, are available in generic form at very low cost in over 100 low- and middle-income countries, yet few countries have launched national campaigns. In Morocco, more than 350,000 people are infected with chronic HCV infection yet only 1,500 individuals with mandatory social health insurance are currently treated each year with DAAs. Such treatment coverage is low for this group and is completely inaccessible to the remaining 70% of the population.
# Methods
To accelerate progress in Morocco, our team of advocates, clinicians, and health policy analysts developed an investment case, using a novel set of tools, that modeled HCV elimination by 2030 and estimated the health impact, costs, cost-effectiveness, return on investment, and budget implications of such an effort.
# Results
Our analysis suggests that Morocco could eliminate HCV and save over 50,000 lives by investing US\$650-715 million in a highly cost-effective manner (US\$1,700 per DALY averted, less than half per capita GDP) and by allocating 3.5% of the Ministry of Health's budget.
# Conclusions
The investment case has been accepted by the Ministry of Health, and Morocco has committed to putting 6,500 patients on treatment in the public sector in 2018-2019 for the first time, targeting the poorest who are eligible for a new social health insurance program. Our experience shows how the investment case method we followed can be used to drive decisions on HCV elimination in favor of more efficient and equitable use of resources. |
| format | Article |
| id | doaj-art-a275a1d70add480fbb25e392ba04d22d |
| institution | DOAJ |
| issn | 2399-1623 |
| language | English |
| publishDate | 2019-03-01 |
| publisher | Inishmore Laser Scientific Publishing Ltd |
| record_format | Article |
| series | Journal of Global Health Reports |
| spelling | doaj-art-a275a1d70add480fbb25e392ba04d22d2025-08-20T02:40:11ZengInishmore Laser Scientific Publishing LtdJournal of Global Health Reports2399-16232019-03-01310.29392/joghr.3.e2019011Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to actionRobert HechtMiloud KaddarStephen ReschJean Luc El KaimChase PerfectMustapha SodqiHakima HimmichLindsey Hiebert# Background Worldwide more than 125 million people are infected with hepatitis C (HCV). New drugs, direct acting antivirals (DAAs) that can cure HCV in three months, are available in generic form at very low cost in over 100 low- and middle-income countries, yet few countries have launched national campaigns. In Morocco, more than 350,000 people are infected with chronic HCV infection yet only 1,500 individuals with mandatory social health insurance are currently treated each year with DAAs. Such treatment coverage is low for this group and is completely inaccessible to the remaining 70% of the population. # Methods To accelerate progress in Morocco, our team of advocates, clinicians, and health policy analysts developed an investment case, using a novel set of tools, that modeled HCV elimination by 2030 and estimated the health impact, costs, cost-effectiveness, return on investment, and budget implications of such an effort. # Results Our analysis suggests that Morocco could eliminate HCV and save over 50,000 lives by investing US\$650-715 million in a highly cost-effective manner (US\$1,700 per DALY averted, less than half per capita GDP) and by allocating 3.5% of the Ministry of Health's budget. # Conclusions The investment case has been accepted by the Ministry of Health, and Morocco has committed to putting 6,500 patients on treatment in the public sector in 2018-2019 for the first time, targeting the poorest who are eligible for a new social health insurance program. Our experience shows how the investment case method we followed can be used to drive decisions on HCV elimination in favor of more efficient and equitable use of resources.https://doi.org/10.29392/joghr.3.e2019011 |
| spellingShingle | Robert Hecht Miloud Kaddar Stephen Resch Jean Luc El Kaim Chase Perfect Mustapha Sodqi Hakima Himmich Lindsey Hiebert Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action Journal of Global Health Reports |
| title | Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action |
| title_full | Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action |
| title_fullStr | Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action |
| title_full_unstemmed | Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action |
| title_short | Morocco investment case for hepatitis C: using analysis to drive the translation of political commitment to action |
| title_sort | morocco investment case for hepatitis c using analysis to drive the translation of political commitment to action |
| url | https://doi.org/10.29392/joghr.3.e2019011 |
| work_keys_str_mv | AT roberthecht moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction AT miloudkaddar moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction AT stephenresch moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction AT jeanlucelkaim moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction AT chaseperfect moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction AT mustaphasodqi moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction AT hakimahimmich moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction AT lindseyhiebert moroccoinvestmentcaseforhepatitiscusinganalysistodrivethetranslationofpoliticalcommitmenttoaction |